We’re live in Phoenix for the 2026 @sitcancer Annual Meeting!

Follow along today and all weekend for coverage of emerging data, expert interviews, and more #SITC26 #oncology

Phase 3 data from China showed the DNA immunotherapy VGX-3100 significantly improved rates of histologic regression with concurrent HPV-16/18 clearance vs placebo in HPV-16/18–associated cervical high-grade squamous intraepithelial lesions @sitcancer #SITC26 #gynsm #oncology co/3KqcewY8GS

Phase 2 translational data showed the peptide-based neoantigen vaccine EVX-01 plus pembrolizumab generated T-cell responses against patient-specific neoantigens and was associated with changes in circulating immune cell populations in advanced melanoma @sitcancer #SITC26 #melsm onclive.com/view/evx-01-pl…

Treatment with the allogeneic g-NK cell therapy IDP-023 plus isatuximab yielded responses in heavily pretreated R/R multiple myeloma, including in those who received prior T-cell–redirecting therapy @sitcancer #SITC26 #mmsm #oncology

Read more from a phase 1 study: onclive.com/view/idp-023-p…

WATCH: @YanaNajjarMD of @UPMCHillmanCC discusses data for the oncolytic vaccinia virus VET3-TGI in patients with advanced solid tumors, with notable activity in cutaneous malignancies @sitcancer #SITC26 #melsm #oncology

onclive.com/view/dr-najjar…

Thank you to @LauraGrahamMD of @CUCancerCenter
for stopping by to discuss her @sitcancer
presentation on phase 1 data for the PSMAxCD28 T-cell engager JNJ-87189401 plus pasritamig in mCRPC.

Stay tuned for her presentation on Saturday at #SITC26!

WATCH: Daniel W. Lee, III, MD, of @UVACancerCenter discussed a first-in-child case in which polatuzumab vedotin plus glofitamab, then modulated CD19-directed CAR T-cell therapy, induced remission in a pediatric patient with primary refractory Burkitt lymphoma @sitcancer #SITC26 #lymsm #oncology

onclive.com/view/dr-lee-on…

WATCH 👀: Suzanne B. Merrill, MD, FACS, of Colorado Urology discusses patient selection and toxicity considerations for BCG plus durvalumab in BCG-naive, high-risk NMIBC.

See the full video here ➡️: onclive.com/view/dr-merril…

#blcsm #oncology #LUGPA02026 @UrologyUS

🧬 Median OS of 57.4 vs 46.5 months (HR, 0.82) with capivasertib plus abiraterone in PTEN-deficient mHSPC, per updated CAPItello-281 data. @Daniel_J_George, of @DukeGUCancer, reviewed the longer follow-up at #LUGPA2026 👇 @UrologyUS #pcsm hubs.li/Q04DFFXj0

WATCH 👀: Benjamin Garmezy, MD, of @SarahCannonDocs discusses how biomarkers, toxicity, and patient preferences guide treatment intensification in advanced prostate cancer.

Full video here ➡️: onclive.com/view/dr-garmez…

#oncology #pcsm #LUGPA2026 @UrologyUS

Think you know oncology?

Test how up-to-date your knowledge is with this week's news quiz!

Take the quiz here ➡️: onclive.com/view/onclive-w…

#oncology

📊 BCG now delivers ~80%-85% 2-year recurrence-free survival in contemporary phase 3 trials, well above the old 60%-65% benchmark. @VigneshPackiam, of @RutgersCancer, makes the case for BCG as the first move in BCG-naive high-risk NMIBC 👇 @UrologyUS @rwjurology #LUGPA2026 #blcsm hubs.li/Q04DFmrp0

From 6-year NATALEE OS to Dato-DXd in brain metastases: 5 ESMO 2026 breast cancer readouts worth knowing. Hope S. Rugo, MD, FASCO, Rebecca Dent, MD, MSc, and Federica Gatti, MD weigh in.

Read the full analysis on OncLive®: onclive.com/view/breast-ca…

@hoperugo @cityofhope @SapienzaRoma #bcsm #ESMO26 #NATALEE

How often do you monitor cardiac function during adjuvant trastuzumab-based therapy?

Does your practice have a formal ILD/pneumonitis monitoring protocol for patients receiving T-DXd for early-stage HER2+ BC?

How do patient priorities shape BCG-unresponsive #NMIBC care? @KSMurrayUro of @NYUUrology discusses response durability, toxicity, and practical considerations for bladder-preserving therapy at #LUGPA2026.

➡️ Read more: hubs.li/Q04DC_Z70

In ES-SCLC, myelosuppression means dose delays, reductions, and hospitalizations that put chemo delivery at risk. Megan May, PharmD, BCOP, FHOPA, FAPO, Taylor Praska, PharmD, and Amanda Edmond, PA-C break down the burden.

Explore the OncLive® Insights series: hubs.li/Q04zxsB60

@BaptistHealth @Bannermdandersn @BannerHealth #lcsm #SCLC #SupportiveCare

Getting a patient with early relapsed multiple myeloma to CAR T starts well before infusion. Joshua Richter, MD, and Doris Hansen, MD, on early referral and bridging that protects T-cell fitness.

Explore the OncLive® Insights series: hubs.li/Q04zw_HZ0

@JoshuaRichterMD tSinai @MountSinaiNYC @MoffittNews #mmsm #CARTcell

In ES-SCLC, myelosuppression means dose delays, reductions, and hospitalizations that put chemo delivery at risk. Megan May, PharmD, BCOP, FHOPA, FAPO, Taylor Praska, PharmD, and Amanda Edmond, PA-C break down the burden.

Explore the OncLive® Insights series: hubs.li/Q04zxsB60

@BaptistHealth @Bannermdandersn @BannerHealth #lcsm #SCLC #SupportiveCare

The countdown is on! In just days, oncology professionals will gather in New York City for Rethinking Skin Cancer Care.  

What's the right sequence of therapy for your patients? Get your questions answered on November 10 at this Live Skin Cancer Summit where expert faculty and ing in practice. The day runs from 9 AM to 3 PM ET at the New York Hilton Midtown, and you'll also receive half off your registration for the upcoming CFS conference! 

Reserve your spot: hubs.ly/Q04ymBXB0  
 #SkinCancer #Oncology #CFS